Combining Dyad Protonation and Active Site Plasticity in BACE-1 Structure-Based Drug Design
暂无分享,去创建一个
Andrea Cavalli | Giovanni Bottegoni | Matteo Masetti | Puneet Kacker | Martina Mangold | A. Cavalli | G. Bottegoni | Matteo Masetti | P. Kacker | M. Mangold
[1] R. Silvestri. Boom in the Development of Non‐Peptidic β‐Secretase (BACE1) Inhibitors for the Treatment of Alzheimer′s Disease , 2009 .
[2] A. Caflisch,et al. Functional Plasticity in the Substrate Binding Site of β-Secretase , 2005 .
[3] G. McGaughey,et al. Structure-guided design of β-secretase (BACE-1) inhibitors , 2007, Expert opinion on drug discovery.
[4] Maxim Totrov,et al. Atomic Property Fields: Generalized 3D Pharmacophoric Potential for Automated Ligand Superposition, Pharmacophore Elucidation and 3D QSAR , 2007, Chemical biology & drug design.
[5] György M. Keserü,et al. Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE against JNK-3 and beta-Secretase , 2006, J. Chem. Inf. Model..
[6] R. Abagyan,et al. Systematic Exploitation of Multiple Receptor Conformations for Virtual Ligand Screening , 2011, PloS one.
[7] D. Small,et al. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions , 2010, Biological chemistry.
[8] D. Rich,et al. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. , 2002, Journal of medicinal chemistry.
[9] Christopher I. Bayly,et al. Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..
[10] Gyoergy M. Keserue,et al. Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE Against JNK-3 and β-Secretase. , 2006 .
[11] Amedeo Caflisch,et al. On the orientation of the catalytic dyad in aspartic proteases , 2010, Proteins.
[12] R. J. Kelleher,et al. γ-Secretase and Human Disease , 2010, Science.
[13] Erik Lindström,et al. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. , 2010, Biochemistry.
[14] M. Citron. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[15] Ruben Abagyan,et al. Recipes for the Selection of Experimental Protein Conformations for Virtual Screening , 2010, J. Chem. Inf. Model..
[16] Yongzhou Hu,et al. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. , 2009, Current medicinal chemistry.
[17] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[18] Kenneth M Merz,et al. Assigning the protonation states of the key aspartates in β-Secretase using QM/MM X-ray structure refinement. , 2006, Journal of chemical theory and computation.
[19] Migliore Amico. Ensemble-docking approach on BACE-1 : Pharmacophore Perception and Guidelines for Drug Design , .
[20] B. Turk. Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.
[21] Robin Taylor,et al. Comparing protein–ligand docking programs is difficult , 2005, Proteins.
[22] L Hong,et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.
[23] Hwangseo Park,et al. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. , 2003, Journal of the American Chemical Society.
[24] Jonathan W. Essex,et al. Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments , 2010, J. Chem. Inf. Model..
[25] Charles H. Reynolds,et al. Modeling the Protonation States of the Catalytic Aspartates in β-Secretase , 2004 .
[26] Romano Silvestri,et al. Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease , 2009, Medicinal research reviews.
[27] Tímea Polgár,et al. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. , 2005, Journal of medicinal chemistry.